humanized CD7 CAR-T cells

Humanized CD7 CAR-T cells represent an advanced cell therapy designed to treat CD7-positive hematological malignancies, primarily T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoblastic lymphoma (T-LBL), and acute myeloid leukemia (AML). This therapy involves engineering a patient's or donor's T cells to express a chimeric antigen receptor (CAR) that specifically recognizes and binds to the CD7 protein found on the surface of malignant cells. A significant challenge in developing CD7 CAR-T cells is 'fratricide,' where the CAR-T cells, which also express CD7, attack each other. To overcome this, various strategies are employed, including gene editing (e.g., CRISPR/Cas9 to knock out the CD7 gene in the CAR-T cells) or the use of protein expression blockers (PEBL) to prevent CD7 surface expression on the CAR-T cells, thereby making them 'fratricide-resistant' and enhancing their persistence and anti-tumor efficacy. The humanized aspect typically refers to the CAR construct being engineered to minimize immunogenicity in human patients.

Other names

CD7 CAR-T cellsCD-7 CAR-T cellsCD 7 CAR-T cellsCD7-targeted CAR T cellsCD-7-targeted CAR T cellsCD 7-targeted CAR T cells